NCT01631903已完成2 期
A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
- 主要终点
- Bleeding Scores
研究概览
简要总结
The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four doses of vaginally administered Proellex in premenopausal women with uterine fibroids confirmed by ultrasound.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 47 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed by ultrasound. Normal, or abnormal but non-clinically significant, transvaginal ultrasound. History of menstrual events occurring in regular cycles.
- •Agreement not to attempt to become pregnant.
- •Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit.
- •Ability to complete a daily subject diary and study procedures in compliance with the protocol.
- •Agrees to use the condoms provided and no other method of birth control (hormonal methods, contraceptive sponge, spermicide or cervical cap) over the course of the study.
- •Has a negative pregnancy test at the Screening and Baseline visits. An exception for the pregnancy test requirement will be granted for subjects providing verification of surgical sterilization.
- •A Body Mass Index (BMI) between 18 and 39 inclusive.
- •Is available for all treatment and follow-up visits.
- •Subject is able to insert vaginal suppositories.
- •Subject is willing to exclusively use sanitary napkins (no tampons) during study duration.
排除标准
- •Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy.
- •Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 7 month study period.
- •Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5x ULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).
- •Received an investigational drug in the 30 days prior to the screening for this study.
- •Women with a history of PCOS.
- •Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
- •Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the preceding 6 months.
- •Has an IUD in place.
- •Women currently using narcotics.
- •Women currently taking cimetidine or spironolactone.
- •Clinically significant abnormal findings on screening examination or any condition, which in the opinion of the investigator, would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study.
- •Participation in study ZP-204.
研究组 & 干预措施
Arm 2 (3mg)
Experimental
干预措施: telepristone acetate 3 mg (Drug)
Arm 3 (6 mg)
Experimental
干预措施: telepristone acetate 6 mg (Drug)
Arm 4 (12 mg)
Experimental
干预措施: telepristone acetate 12 mg (Drug)
Arm 5 (24 mg)
Experimental
干预措施: telepristone acetate 24 mg (Drug)
PK arm (12 mg)
Experimental
PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
干预措施: telepristone acetate 12 mg (Drug)
结局指标
主要结局
Bleeding Scores
时间窗: 3 or 4 months depending on treatment arm
The primary efficacy endpoint will be bleeding assessed using the change in PBAC scores from the 4 weeks prior to Visit 2 to the 4 weeks prior to Visit 10
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Chronic Lymphocytic LeukemiaNCT00963105Celgene104
已完成
2 期
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney StonesSecondary HyperoxaluriaNephrolithiasisKidney StonesHyperoxaluriaDietary HyperoxaluriaNCT02503345Allena Pharmaceuticals32
已完成
2 期
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic PatientsDiabetes Mellitus, Type 2NCT00789035Boehringer Ingelheim408
已完成
1 期
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary Disease (COPD)NCT00545311Novartis40
终止
2 期
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.Gram-negative Bacterial InfectionNCT04126031Pfizer48